pGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N
CAS No. ——
pGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N( —— )
Catalog No. M23001 CAS No. ——
pGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N is a peptides.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 577 | In Stock |
|
| 10MG | 963 | In Stock |
|
| 25MG | 1424 | In Stock |
|
| 50MG | 2181 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamepGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N
-
NoteResearch use only, not for human use.
-
Brief DescriptionpGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N is a peptides.
-
DescriptionpGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N is a peptides.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N[C@H](C(=O)NCC(=O)N[C@@H](Cc1cncn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)C(C)C)[C@H](C)NC(=O)[C@H](Cc3cnc2ccccc23)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H]4CCC(=O)N4)CCCCNc5ccc(c6onnc56)[N+]([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PA-8
PA-8 is a small molecule receptor antagonist for PACAP Type I (PAC1) that is selective, effective, and orally active. PA-8 inhibits PacAP-induced CREB phosphorylation at PAC1- receptors, but does not inhibit VPAC1- or vpac2 receptors.
-
CJ-42794
CJ-42794 is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5).
-
MID-1
MID-1 is an inhibitor of MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction.?It disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake.
Cart
sales@molnova.com